Management Strategies for Relapsed/Refractory Multiple Myeloma: Current Clinical Perspectives

Seminars in Hematology

Volumn 49, Issue SUPPL. 1, 2012, Pages

  Jakubowiak, Andrzej ^a  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BORTEZOMIB; CARMUSTINE; CISPLATIN; CLODRONIC ACID; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ENOXAPARIN; ETOPOSIDE; LENALIDOMIDE; MELPHALAN; METHYLPREDNISOLONE; PAMIDRONIC ACID; PARACETAMOL; PLACEBO; PREDNISONE; THALIDOMIDE; VINCRISTINE; WARFARIN; ZOLEDRONIC ACID;

ALLOGENEIC STEM CELL TRANSPLANTATION; ANEMIA; ARTICLE; ASTHENIA; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE LESION; BONE MARROW SUPPRESSION; BONE PAIN; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER RELAPSE; CANCER SURVIVAL; CONSTIPATION; DEPRESSION; DIARRHEA; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG EXCRETION; DRUG MEGADOSE; DRUG METABOLISM; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELDERLY CARE; FATIGUE; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; GENE MUTATION; GENETIC HETEROGENEITY; HAND FOOT SYNDROME; HEART ATRIUM FIBRILLATION; HEART DISEASE; HUMAN; HYPERCALCEMIA; INFECTION; LOW DRUG DOSE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NAUSEA; NEUROPATHY; NEUTROPENIA; NONHUMAN; PATHOLOGIC FRACTURE; PATIENT CARE; PERIPHERAL NEUROPATHY; PERSONALIZED MEDICINE; PRIORITY JOURNAL; SALVAGE THERAPY; SENSORY NEUROPATHY; SKIN TOXICITY; SOMNOLENCE; SPINAL CORD COMPRESSION; THROMBOCYTOPENIA; VENOUS THROMBOEMBOLISM; VOMITING;

ANTINEOPLASTIC AGENTS; HUMANS; MULTIPLE MYELOMA; RECURRENCE;

EID: 84862665352     PISSN: 00371963     EISSN: 15328686     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2012.05.003     Document Type: Article

References (154)

1. Alexanian R., Barlogie B., Tucker S. VAD-based regimens as primary treatment for multiple myeloma. Am J Hematol 1990, 33:86-89.
2. Alexanian R., Bergsagel D.E., Migliore P.J., Vaughn W.K., Howe C.D. Melphalan therapy for plasma cell myeloma. Blood 1968, 31:1-10.
3. Alexanian R., Dimopoulos M.A., Delasalle K., Barlogie B. Primary dexamethasone treatment of multiple myeloma. Blood 1992, 80:887-890.
4. Alexanian R., Dimopoulos M.A., Delasalle K.B., Hester J., Champlin R. Myeloablative therapy for primary resistant multiple myeloma. Stem Cells 1995, 13(Suppl 2):118-121.
5. Attal M., Harousseau J.L., Stoppa A.M., et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome. N Engl J Med 1996, 335:91-97.
6. Kumar S.K., Therneau T.M., Gertz M.A., et al. Clinical course of patients with relapsed multiple myeloma. Mayo Clin Proc 2004, 79:867-874.
7. Dimopoulos M.A., San-Miguel J.F., Anderson K.C. Emerging therapies for the treatment of relapsed or refractory multiple myeloma. Eur J Haematol 2011, 86:1-15.
8. Kim Y.K., Sohn S.K., Lee J.H., et al. Korean Multiple Myeloma Working Party (KMMWP). Clinical efficacy of a bortezomib, cyclophosphamide, thalidomide, and dexamethasone (Vel-CTD) regimen in patients with relapsed or refractory multiple myeloma: a phase II study. Ann Hematol 2010, 89:475-482.
9. San Miguel J.F. Relapse/refractory myeloma patient: potential treatment guidelines. J Clin Oncol 2009, 27:5676-5677.
10. Mohty B., El-Cheikh J., Yakoub-Agha I., Avet-Loiseau H., Moreau P., Mohty M. Treatment strategies in relapsed and refractory multiple myeloma: a focus on drug sequencing and 'retreatment' approaches in the era of novel agents. Leukemia 2012, 26:73-85.
11. National Comprehensive Cancer Network (NCCN) clinical practice guidelines in oncology. Multiple myeloma. Version 1.2012.
12. Harousseau J.L., Dreyling M. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010, 21(Suppl 5):v155-v157. ESMO Guidelines Working Group.
13. Barlogie B., Alexanian R., Dicke K.A., et al. High-dose chemoradiotherapy and autologous bone marrow transplantation for resistant multiple myeloma. Blood 1987, 70:869-872.
14. Barlogie B., Hall R., Zander A., Dicke K., Alexanian R. High-dose melphalan with autologous bone marrow transplantation for multiple myeloma. Blood 1986, 67:1298-1301.
15. Alexanian R., Barlogie B., Dixon D. High-dose glucocorticoid treatment of resistant myeloma. Ann Intern Med 1986, 105:8-11.
16. Gertz M.A., Garton J.P., Greipp P.R., Witzig T.E., Kyle R.A. A phase II study of high-dose methylprednisolone in refractory or relapsed multiple myeloma. Leukemia 1995, 9:2115-2118.
17. Barlogie B., Smith L., Alexanian R. Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med 1984, 310:1353-1356.
18. Gertz M.A., Kalish L.A., Kyle R.A., Hahn R.G., Tormey D.C., Oken M.M. Phase III study comparing vincristine, doxorubicin (Adriamycin), and dexamethasone (VAD) chemotherapy with VAD plus recombinant interferon alfa-2 in refractory or relapsed multiple myeloma. An Eastern Cooperative Oncology Group study. Am J Clin Oncol 1995, 18:475-480.
19. Lokhorst H.M., Meuwissen O.J., Bast E.J., Dekker A.W. VAD chemotherapy for refractory multiple myeloma. Br J Haematol 1989, 71:25-30.
20. Phillips J.K., Sherlaw-Johnson C., Pearce R., et al. A randomized study of MOD versus VAD in the treatment of relapsed and resistant multiple myeloma. Leuk Lymphoma 1995, 17:465-472.
21. Durie B.G., Dixon D.O., Carter S., et al. Improved survival duration with combination chemotherapy induction for multiple myeloma: a Southwest Oncology Group study. J Clin Oncol 1986, 4:1227-1237.
22. Giles F.J., Wickham N.R., Rapoport B.L., et al. Cyclophosphamide, etoposide, vincristine, adriamycin, and dexamethasone (CEVAD) regimen in refractory multiple myeloma: an International Oncology Study Group (IOSG) phase II protocol. Am J Hematol 2000, 63:125-130.
23. Anderson H., Scarffe J.H., Ranson M., et al. VAD chemotherapy as remission induction for multiple myeloma. Br J Cancer 1995, 71:326-330.
24. Dadacaridou M., Papanicolaou X., Maltesas D., et al. Dexamethasone, cyclophosphamide, etoposide and cisplatin (DCEP) for relapsed or refractory multiple myeloma patients. J Buon 2007, 12:41-44.
25. Lee C.K., Barlogie B., Munshi N., et al. DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma. J Clin Oncol 2003, 21:2732-2739.
26. Munshi N., Desikan K., Jagannath S., et al. Dexamethasone, cyclophosphamide, etoposide and cisplatinum (DCEP), an effective regimen for relapse after high-dose chemotherapy and autologous transplantation (AT). Blood 1996, 88. abstract 586a.
27. Garban F., Attal M., Michallet M., et al. Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. Blood 2006, 107:3474-3480.
28. Gahrton G., Tura S., Ljungman P., et al. Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma. J Clin Oncol 1995, 13:1312-1322.
29. Kröger N., Perez-Simon J.A., Myint H., et al. Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma. Biol Blood Marrow Transplant 2004, 10:698-708.
30. Burzynski J.A., Toro J.J., Patel R.C., et al. Toxicity of a second autologous peripheral blood stem cell transplant in patients with relapsed or recurrent multiple myeloma. Leuk Lymphoma 2009, 50:1442-1447.
31. Elice F., Raimondi R., Tosetto A., et al. Prolonged overall survival with second on-demand autologous transplant in multiple myeloma. Am J Hematol 2006, 81:426-431.
32. Krivanová A., Hájek R., Krejcí M., et al. Second autologous transplantation for multiple myeloma patients relapsing after the first autograft-a pilot study for the evaluation of experimental maintenance therapies. Report of the prospective non-randomized pilot study of the. Onkologie 2004, 27:275-279. Czech Myeloma Group.
33. Olin R.L., Vogl D.T., Porter D.L., et al. Second auto-SCT is safe and effective salvage therapy for relapsed multiple myeloma. Bone Marrow Transplant 2009, 43:417-422.
34. Qazilbash M.H., Saliba R., De Lima M., et al. Second autologous or allogeneic transplantation after the failure of first autograft in patients with multiple myeloma. Cancer 2006, 106:1084-1089.
35. Alvares C.L., Davies F.E., Horton C., Patel G., Powles R., Morgan G.J. The role of second autografts in the management of myeloma at first relapse. Haematologica 2006, 91:141-142.
36. Singhal S., Mehta J., Desikan R., et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999, 341:1565-1571.
37. Barlogie B., Desikan R., Eddlemon P., et al. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood 2001, 98:492-494.
38. Tosi P., Zamagni E., Cellini C., et al. Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma. Haematologica 2002, 87:408-414.
39. Yakoub-Agha I., Attal M., Dumontet C., et al. Thalidomide in patients with advanced multiple myeloma: a study of 83 patients-report of the Intergroupe Françophone du Myelome (IFM). Hematol J 2002, 3:185-192.
40. Juliusson G., Celsing F., Turesson I., Lenhoff S., Adriansson M., Malm C. Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma. Br J Haematol 2000, 109:89-96.
41. Richardson P., Schlossman R., Jagannath S., et al. Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activity. Mayo Clin Proc 2004, 79:875-882.
42. Hus M., Dmoszynska A., Soroka-Wojtaszko M., et al. Thalidomide treatment of resistant or relapsed multiple myeloma patients. Haematologica 2001, 86:404-408. Polish Multiple Myeloma Study Group.
43. Wu K.L., Helgason H.H., van der Holt B., et al. Analysis of efficacy and toxicity of thalidomide in 122 patients with multiple myeloma: response of soft-tissue plasmacytomas. Leukemia 2005, 19:143-145.
44. Mileshkin L., Biagi J.J., Mitchell P., et al. Multicenter phase 2 trial of thalidomide in relapsed/refractory multiple myeloma: adverse prognostic impact of advanced age. Blood 2003, 102:69-77.
45. Waage A., Gimsing P., Juliusson G., et al. Early response predicts thalidomide efficiency in patients with advanced multiple myeloma. Br J Haematol 2004, 125:149-155.
46. Glasmacher A., Hahn C., Hoffmann F., et al. A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma. Br J Haematol 2006, 132:584-593.
47. Yakoub-Agha I., Mary J.Y., Hulin C., et al. Low-dose v. high-dose thalidomide for advanced multiple myeloma: a prospective trial from the Intergroupe Francophone du Myelome. Eur J Haematol 2012, 88:249-259.
48. Kropff M., Giongco-Baylon H., Hillengass J., et al. Thalidomide versus dexamethasone for the treatment of relapsed and/or refractory multiple myeloma: results from OPTIMUM, a randomized trial. Haematologica 2012, 97:784-791.
49. García-Sanz R., González-Porras J.R., Hernández J.M., et al. The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed/refractory multiple myeloma. Leukemia 2004, 18:856-863.
50. Kyriakou C., Thomson K., D'Sa S., et al. Low-dose thalidomide in combination with oral weekly cyclophosphamide and pulsed dexamethasone is a well tolerated and effective regimen in patients with relapsed and refractory multiple myeloma. Br J Haematol 2005, 129:763-770.
51. Roussou M., Anagnostopoulos A., Kastritis E., et al. Pulsed cyclophosphamide, thalidomide and dexamethasone regimen for previously treated patients with multiple myeloma: long term follow up and disease control after subsequent treatments. Leuk Lymphoma 2007, 48:754-758.
52. Morris T.C., Kettle P.J., Drake M., et al. Clarithromycin with low dose dexamethasone and thalidomide is effective therapy in relapsed/refractory myeloma. Br J Haematol 2008, 143:349-354.
53. Anagnostopoulos A., Weber D., Rankin K., Delasalle K., Alexanian R. Thalidomide and dexamethasone for resistant multiple myeloma. Br J Haematol 2003, 121:768-771.
54. Palumbo A., Avonto I., Bruno B., et al. Intravenous melphalan, thalidomide and prednisone in refractory and relapsed multiple myeloma. Eur J Haematol 2006, 76:273-277.
55. Palumbo A., Giaccone L., Bertola A., et al. Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma. Haematologica 2001, 86:399-403.
56. Palumbo A., Bertola A., Falco P., et al. Efficacy of low-dose thalidomide and dexamethasone as first salvage regimen in multiple myeloma. Hematol J 2004, 5:318-324.
57. Alexanian R., Weber D., Anagnostopoulos A., Delasalle K., Wang M., Rankin K. Thalidomide with or without dexamethasone for refractory or relapsing multiple myeloma. Semin Hematol 2003, 40(4 suppl 4):3-7.
58. Dimopoulos M.A., Zervas K., Kouvatseas G., et al. Thalidomide and dexamethasone combination for refractory multiple myeloma. Ann Oncol 2001, 12:991-995.
59. Kropff M.H., Lang N., Bisping G., et al. Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma. Br J Haematol 2003, 122:607-616.
60. Dimopoulos M.A., Hamilos G., Zomas A., et al. Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen for previously treated patients with multiple myeloma. Hematol J 2004, 5:112-117.
61. Sidra G., Williams C.D., Russell N.H., Zaman S., Myers B., Byrne J.L. Combination chemotherapy with cyclophosphamide, thalidomide and dexamethasone for patients with refractory, newly diagnosed or relapsed myeloma. Haematologica 2006, 91:862-863.
62. Hovenga S., Daenen S.M., de Wolf J.T., et al. Combined thalidomide and cyclophosphamide treatment for refractory or relapsed multiple myeloma patients: a prospective phase II study. Ann Hematol 2005, 84:311-316.
63. Offidani M., Marconi M., Corvatta L., Olivieri A., Catarini M., Leoni P. Thalidomide plus oral melphalan for advanced multiple myeloma: a phase II study. Haematologica 2003, 88:1432-1433.
64. Srkalovic G., Elson P., Trebisky B., Karam M.A., Hussein M.A. Use of melphalan, thalidomide, and dexamethasone in treatment of refractory and relapsed multiple myeloma. Med Oncol 2002, 19:219-226.
65. Offidani M., Corvatta L., Marconi M., et al. Low-dose thalidomide with pegylated liposomal doxorubicin and high-dose dexamethasone for relapsed/refractory multiple myeloma: a prospective, multicenter, phase II study. Haematologica 2006, 91:133-136.
66. Hussein M.A., Baz R., Srkalovic G., et al. Phase 2 study of pegylated liposomal doxorubicin, vincristine, decreased-frequency dexamethasone, and thalidomide in newly diagnosed and relapsed-refractory multiple myeloma. Mayo Clin Proc 2006, 81:889-895.
67. Moehler T.M., Neben K., Benner A., et al. Salvage therapy for multiple myeloma with thalidomide and CED chemotherapy. Blood 2001, 98:3846-3848.
68. Muller G.W., Chen R., Huang S.Y., et al. Amino-substituted thalidomide analogs: potent inhibitors of TNF-alpha production. Bioorg Med Chem Lett 1999, 9:1625-1630.
69. Richardson P.G., Schlossman R.L., Weller E., et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 2002, 100:3063-3067.
70. Richardson P., Jagannath S., Hussein M., et al. Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma. Blood 2009, 114:772-778.
71. Zangari M.T.G., Zeldis J., Eddlemon P., Saghafifar F., Barlogie B. Results of phase I study of CC-5013 for the treatment of multiple myeloma patients who relapse after high dose chemotherapy (HDCT). Blood 2001, abstract 3226.
72. Weber D.M., Chen C., Niesvizky R., et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007, 357:2133-2142.
73. Dimopoulos M., Spencer A., Attal M., et al. Multiple Myeloma 9010) Study Investigators. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007, 357:2123-2132.
74. Baz R., Walker E., Karam M.A., et al. Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy. Ann Oncol 2006, 17:1766-1771.
75. Knop S., Gerecke C., Liebisch P., et al. Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom). Blood 2009, 113:4137-4143.
76. Reece D.E., Masih-Kahn M., Khan A., et al. Phase I-II trial of oral cyclophosphamide, prednisone and lenalidomide (revlimid(R)) (CPR) for the treatment of patients with relapsed and refractory multiple myeloma. Blood 2009, 114. abstract 1874.
77. Schey S., Morgan G., Ramasamy K., et al. CRD: a phase 1 dose escalation study to determine the maximum tolerated dose of cyclophosphamide in combination with lenalidomide and dexamethasone in relapsed/refractory myeloma. Blood 2008, 112. abstract 3707.
78. Dimopoulos M.A., Chen C., Spencer A., et al. Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Leukemia 2009, 23:2147-2152.
79. Touzeau C., Blin N., Clavert A., et al. Efficacy of lenalidomide plus dexamethasone in patients older than 75 years with relapsed multiple myeloma. Leuk Lymphoma 2012 Jan 31, [Epub ahead of print].
80. Rajkumar S.V., Jacobus S., Callander N.S., et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol 2010, 11:29-37. Eastern Cooperative Oncology Group.
81. van de Donk N.W., Wittebol S., Minnema M.C., Lokhorst H.M. Lenalidomide (Revlimid) combined with continuous oral cyclophosphamide (endoxan) and prednisone (REP) is effective in lenalidomide/dexamethasone-refractory myeloma. Br J Haematol 2010, 148:335-337.
82. Morgan G.J., Schey S.A., Wu P., et al. Lenalidomide (Revlimid), in combination with cyclophosphamide and dexamethasone (RCD), is an effective and tolerated regimen for myeloma patients. Br J Haematol 2007, 137:268-269.
83. Orlowski R.Z., Stinchcombe T.E., Mitchell B.S., et al. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol 2002, 20:4420-4427.
84. Richardson P.G., Barlogie B., Berenson J., et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003, 348:2609-2617.
85. Jagannath S., Barlogie B., Berenson J., et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 2004, 127:165-172.
86. Richardson P.G., Sonneveld P., Schuster M.W., et al. ; Assessment of Proteasome Inhibition for Extending Remossions (APEX) Investigators. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005, 352:2487-2498.
87. Richardson P.G., Sonneveld P., Schuster M., et al. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood 2007, 110:3557-3560.
88. Orlowski R.Z., Nagler A., Sonneveld P., et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol 2007, 25:3892-3901.
89. Kropff M., Bisping G., Schuck E., et al. Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma. Br J Haematol 2007, 138:330-337. Deutsche Studiengruppe Multiples Myelom.
90. Palumbo A., Gay F., Bringhen S., et al. Bortezomib, doxorubicin and dexamethasone in advanced multiple myeloma. Ann Oncol 2008, 19:1160-1165.
91. Jakubowiak A.J., Kendall T., Al-Zoubi A., et al. Phase II trial of combination therapy with bortezomib, pegylated liposomal doxorubicin, and dexamethasone in patients with newly diagnosed myeloma. J Clin Oncol 2009, 27:5015-5022.
92. Berenson J.R., Yang H.H., Sadler K., et al. Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma. J Clin Oncol 2006, 24:937-944.
93. Reece D.E., Rodriguez G.P., Chen C., et al. Phase I-II trial of bortezomib plus oral cyclophosphamide and prednisone in relapsed and refractory multiple myeloma. J Clin Oncol 2008, 26:4777-4783.
94. Popat R., Oakervee H., Williams C., et al. Bortezomib, low-dose intravenous melphalan, and dexamethasone for patients with relapsed multiple myeloma. Br J Haematol 2009, 144:887-894.
95. Kropff M.H., Bisping G., Wenning D., et al. Bortezomib in combination with dexamethasone for relapsed multiple myeloma. Leuk Res 2005, 29:587-590.
96. Jagannath S., Richardson P.G., Barlogie B., et al. Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone. Haematologica 2006, 91:929-934. SUMMIT/CREST Investigators.
97. Mikhael J.R., Belch A.R., Prince H.M., et al. High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program. Br J Haematol 2009, 144:169-175.
98. Davies F.E., Wu P., Jenner M., Srikanth M., Saso R., Morgan G.J. The combination of cyclophosphamide, velcade and dexamethasone induces high response rates with comparable toxicity to velcade alone and velcade plus dexamethasone. Haematologica 2007, 92:1149-1150.
99. Ciolli S., Leoni F., Casini C., Breschi C., Santini V., Bosi A. The addition of liposomal doxorubicin to bortezomib, thalidomide and dexamethasone significantly improves clinical outcome of advanced multiple myeloma. Br J Haematol 2008, 141:814-819.
100. Terpos E., Kastritis E., Roussou M., et al. The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis. Leukemia 2008, 22:2247-2256.
101. Palumbo A., Ambrosini M.T., Benevolo G., et al. Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma. Blood 2007, 109:2767-2772. Italian Multiple Myeloma Network; Gruppo Italiano Malattie Ematologicche dell'Adulto.
102. Pineda-Roman M., Zangari M., van Rhee F., et al. VTD combination therapy with bortezomib-thalidomide-dexamethasone is highly effective in advanced and refractory multiple myeloma. Leukemia 2008, 22:1419-1427.
103. Richardson P.G., Weller E., Jagannath S., et al. Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma. J Clin Oncol 2009, 27:5713-5719.
104. Cavallo F., Larocca A., Petrucci M.T., Federico V., Falcone A.P., Sanpaolo G., et al. A prospective randomized phase i/ii study of lenalidomide, melphalan, prednisone and thalidomide (RMPT) for relapsed/refractory multiple myeloma patients. Blood 2009, 114. abstract 2864.
105. Richardson P., Jagannath S., Jakubowiak A., et al. Lenalidomide, bortezomib, and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (MM): encouraging response rates and tolerability with correlation of outcome and adverse cytogenetics in a phase II study. Blood 2008, 112. abstract 1742.
106. Terpos E., Christoulas D., Kastritis E., et al. The addition of bortezomib to the combination of lenalidomide and dexamethasone increases bone formation in relapsed/refractory myeloma: a prospective study in 91 patients. Blood 2009, 114. abstract 1815.
107. Palumbo A., Anderson K. Multiple myeloma. N Engl J Med 2011, 364:1046-1060.
108. von Lilienfeld-Toal M., Hahn-Ast C., Furkert K., et al. A systematic review of phase II trials of thalidomide/dexamethasone combination therapy in patients with relapsed or refractory multiple myeloma. Eur J Haematol 2008, 81:247-252.
109. Schiff D., Wen P.Y., van den Bent M.J. Neurological adverse effects caused by cytotoxic and targeted therapies. Nat Rev Clin Oncol 2009, 6:596-603.
110. Reddy G.K., Mughal T.I., Lonial S. Optimizing the management of treatment-related peripheral neuropathy in patients with multiple myeloma. Support Cancer Ther 2006, 4:19-22.
111. Mateos M.V. Management of treatment-related adverse events in patients with multiple myeloma. Cancer Treat Rev 2010, 36(Suppl 2):S24-S32.
112. van Marion A.M., Auwerda J.J., Lisman T., et al. Prospective evaluation of coagulopathy in multiple myeloma patients before, during and after various chemotherapeutic regimens. Leuk Res 2008, 32:1078-1084.
113. Palumbo A., Rajkumar S.V., Dimopoulos M.A., et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 2008, 22:414-423. International Myeloma Working Group.
114. Minnema M.C., Breitkreutz I., Auwerda J.J., et al. Prevention of venous thromboembolism with low molecular-weight heparin in patients with multiple myeloma treated with thalidomide and chemotherapy. Leukemia 2004, 18:2044-2046.
115. Zangari M., Barlogie B., Anaissie E., et al. Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation. Br J Haematol 2004, 126:715-721.
116. Niesvizky R., Martinez-Baños D., Jalbrzikowski J., et al. Prophylactic low-dose aspirin is effective antithrombotic therapy for combination treatments of thalidomide or lenalidomide in myeloma. Leuk Lymphoma 2007, 48:2330-2337.
117. Palumbo A., Facon T., Sonneveld P., et al. Thalidomide for treatment of multiple myeloma: 10 years later. Blood 2008, 111:3968-3977.
118. Summit N.J. Revlimid (lenalidomide), Celgene CorporationCelgene Corporation, [prescribing information], Assessed on Janaury 15, 2012. http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021880s023lbl.pdf.
119. Ludwig H., Durie B.G.M., McCarthy P., et al. IMWG consensus on maintenance therapy in multiple myeloma. Blood 2012, 119:3003-3015.
120. Dimopoulos M.A., Orlowski R.Z., Niesvizky R., et al. Lenalidomide and dexamethasone (LEN plus DEX) treatment in relapsed/refractory multiple myeloma (RRMM) patients (pts) and risk of second primary malignancies (SPM): Analysis of MM-009/010. J Clin Oncol 2011, 29(suppl). abstract 8009.
121. Richardson P., Jagannath S., Colson K. Optimizing the efficacy and safety of bortezomib in relapsed multiple myeloma. Clin Adv Hematol Oncol 2006, 4:1. discussion 8; suppl 13.
122. Gay F., Palumbo A. Multiple myeloma: management of adverse events. Med Oncol 2010, 27:646-653.
123. Corso A., Mangiacavalli S., Varettoni M., Pascutto C., Zappasodi P., Lazzarino M. Bortezomib-induced peripheral neuropathy in multiple myeloma: a comparison between previously treated and untreated patients. Leuk Res 2010, 34:471-474.
124. Richardson P.G., Xie W., Mitsiades C., et al. Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy. J Clin Oncol 2009, 27:3518-3525.
125. Bringhen S., Larocca A., Rossi D., et al. Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. Blood 2010, 116:4745-4753.
126. Moreau P., Pylypenko H., Grosicki S., et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol 2011, 12:431-440.
127. Chanan-Khan A., Sonneveld P., Schuster M.W., et al. Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study. J Clin Oncol 2008, 26:4784-4790.
128. Altekruse S, Kosary C, Krapcho M, et al (eds). SEER Cancer Statistics Review 1975-2007. National Cancer Institute. Bethesda, MD, . Based on November 2009 SEER data submission posted to the SEER Website, 2010. Accessed on March 19, 2012. http://seer.cancer.gov/csr/1975-2007/.
129. Palumbo A., Bringhen S., Ludwig H., et al. Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN). Blood 2011, 118:4519-4529.
130. Cancer pain relief and palliative care. Report of a WHO Expert Committee. World Health Organ Tech Rep Ser 1990, 804:1-75.
131. Leigh B.R., Kurtts T.A., Mack C.F., Matzner M.B., Shimm D.S. Radiation therapy for the palliation of multiple myeloma. Int J Radiat Oncol Biol Phys 1993, 25:801-804.
132. Berenson J.R., Lichtenstein A., Porter L., et al. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. J Clin Oncol 1998, 16:593-602. Myeloma Aredia Study Group.
133. Berenson J.R., Lichtenstein A., Porter L., et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med 1996, 334:488-493. Myeloma Aredia Study Group.
134. Morgan G.J., Davies F.E., Gregory W.M., et al. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet 2010, 376:1989-1999. National Cancer Research Institute Haematological Oncology Clinical Study Group.
135. Morgan G.J., Child J.A., Gregory W.M., et al. Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial. Lancet Oncol 2011, 12:743-752. National Cancer Research Institute Haematological Oncology Clinical Study Group.
136. Terpos E., Sezer O., Croucher P.I., et al. The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network. Ann Oncol 2009, 20:1303-1317. European Myeloma Network.
137. Dickinson M., Prince H.M., Kirsa S., et al. Osteonecrosis of the jaw complicating bisphosphonate treatment for bone disease in multiple myeloma: an overview with recommendations for prevention and treatment. Intern Med J 2009, 39:304-316.
138. Dimopoulos M.A., Kastritis E., Rosinol L., Bladé J., Ludwig H. Pathogenesis and treatment of renal failure in multiple myeloma. Leukemia 2008, 22:1485-1493.
139. Stewart A.F. Clinical practice. Hypercalcemia associated with cancer. N Engl J Med 2005, 352:373-379.
140. Rizzo J.D., Somerfield M.R., Hagerty K.L., et al. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update. J Clin Oncol 2008, 26:132-149. American Society of Clinical Oncology; American Society of Hematology.
141. Laubach J.P., Mitsiades C.S., Mahindra A., et al. Management of relapsed and relapsed/refractory multiple myeloma. J Natl Compr Canc Netw 2011, 9:1209-1216.
142. Decaux O., Lodé L., Magrangeas F., et al. Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the Intergroupe Francophone du Myelome. J Clin Oncol 2008, 26:4798-4805. Intergroupe Françophone du Myélome.
143. Jagannath S., Richardson P.G., Sonneveld P., et al. Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials. Leukemia 2007, 21:151-157.
144. San Miguel J.F., Schlag R., Khuageva N.K., et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008, 359:906-917. VISTA Trial Investigators.
145. Avet-Loiseau H., Leleu X., Roussel M., et al. Bortezomib plus dexamethasone induction improves outcome in patients with t(4;14) myeloma but not outcome of patients with del(17p). J Clin Oncol 2010, 28:4630-4634.
146. Neben K., Lokhorst H.M., Jauch A., et al. Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p. Blood 2012, 119:940-948.
147. Knudsen L.M., Hippe E., Hjorth M., Holmberg E., Westin J. Renal function in newly diagnosed multiple myeloma-a demographic study of 1353 patients. Eur J Haematol 1994, 53:207-212. The Nordic Myeloma Study Group.
148. Jagannath S., Barlogie B., Berenson J.R., et al. Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impaired renal function. Cancer 2005, 103:1195-1200. SUMMITT/CREST Investigators.
149. San-Miguel J.F., Richardson P.G., Sonneveld P., et al. Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study. Leukemia 2008, 22:842-849.
150. Tosi P., Zamagni E., Cellini C., et al. Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure. Eur J Haematol 2004, 73:98-103.
151. 2006, Thalomid (thalidomide), [prescribing information], Celgene Corporation, Summit, NJ, Assessed on Janaury 15, 2012. http://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021430lbl.pdf.
152. 2011, Velcade (bortezomib), [prescribing information], Millennium Pharmaceuticals, Inc., Cambridge, MA, Assessed on Janaury 15, 2012. http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021602s029s030lbl.pdf%20Assessed%20on%20Janaury%2015,%202012.
153. Richardson P.G., Briemberg H., Jagannath S., et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 2006, 24:3113-3120.
154. Ludwig H., Beksac M., Bladé J., et al. Current multiple myeloma treatment strategies with novel agents: a European perspective. Oncologist 2010, 15:6-25.